Heat stress induces ferroptosis-like cell death in plants
Xtandi (enzalutamide) Disease area(s): Oncology Manufacturer(s): Astellas/Pfizer 2024 Sales (USD): $7.94 billion Why it sold so well: In 2024, Astellas Pharmas Xtandi, co-marketed with Pfizer, posted strong sales growth, with revenues reaching 703.1 billion ($4.64 billion) for the first nine months (April 1, 2024 to December 31, 2024), marking a 25.6% increase compared to the same period in the previous year
Ro includes weekly coaching
www.mdpi.com, Mbikay, Majambu, et al
The FDA has not approved it for human use or medical treatment
A HerKare provider can help determine whether options like Tirzepatide may be right for you